ReNAgade is acquired by RNA rival a year after megaround-backed launch

Ryan Cross

Senior Science Correspondent

Two buzzy, well-funded biotech startups are combining in a bid to create a powerhouse at the bleeding edge of genetic medicines.
Orna Therapeutics announced Thursday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ReNAgade is acquired by RNA rival a year after megaround-backed launch

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

The brain is Eli Lilly's next target for its obesity meds

The Endpoints 100: The biotech industry braces for Trump 2.0

During Covid, RFK Jr. lobbied against vaccine EUAs for children. As HHS secretary, he could rescind them

Candel’s shares soar on Phase 3 prostate cancer data despite unclear prospects

Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapies

The key to faster, more impactful research? Put patients in the driver’s seat

Re­NA­gade is ac­quired by RNA ri­val a year af­ter megaround-backed launch

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

ReNAgade is acquired by RNA rival a year after megaround-backed launch

The brain is Eli Lilly's next target for its obesity meds

The Endpoints 100: The biotech industry braces for Trump 2.0

During Covid, RFK Jr. lobbied against vaccine EUAs for children. As HHS secretary, he could rescind them

Candel’s shares soar on Phase 3 prostate cancer data despite unclear prospects

Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapies

The key to faster, more impactful research? Put patients in the driver’s seat